Drug pricing transparency

Drug pricing transparency requirements are creating direct friction points for Trade and Geopolitical Risk teams, particularly as the U.S. Centers for Medicare and Medicaid Services and the U.S. Food and Drug Administration push disclosure mandates that touch cross-border supply chain structures and foreign reference pricing arrangements. The Office of the United States Trade Representative has flagged several trading partner pricing regimes as potential non-tariff barriers, meaning what looks like a domestic compliance obligation can carry bilateral trade agreement implications. Compliance teams are currently mapping distributor and licensing agreements against CMS's Drug Price Transparency rule to determine whether foreign counterparty arrangements trigger reportable benchmarks.